Publications by authors named "Lisa Thomas Read"
Background: Tafenoquine is a long-acting 8-aminoquinoline approved for antimalarial prophylaxis for ≤6 months. Additional data is needed to establish the drug's longer-term safety profile, including potential ophthalmic or neuropsychiatric effects.
Method: This was a randomized, double-blind, placebo-controlled trial in 600 healthy adults.
Tafenoquine for malaria prophylaxis in adults: An integrated safety analysis.
Travel Med Infect Dis
October 2017
Article Synopsis
- Tafenoquine is a new preventive drug for malaria, with a safety assessment based on data from five clinical trials involving both deployed military personnel and non-deployed residents.
- The study found that deployment status influenced the incidence of adverse events (AEs), with deployed personnel reporting a higher occurrence of AEs compared to non-deployed participants.
- Key AEs associated with tafenoquine included gastrointestinal issues, infections, and back/neck pain, although the overall rate of AEs did not significantly differ from those receiving placebo.